Participated · Series D · May 2022

Laekna leverages a platform that has enabled the rapid development of 14 innovative drug candidates and has initiated six clinical programs, three of which are multi-regional including one pivotal trial. The company is focused on developing next-generation therapies addressing standard-of-care-resistant cancers and liver diseases. Its two core product candidates are AKT kinase inhibitor afuresertib (LAE002) and a clinical-stage CYP17/CYP11B2 dual inhibitor (LAE001). These candidates cover three differentiated mechanisms: targeted therapy, hormonal therapy, and immuno-oncology therapy. The most advanced program is an open-label, randomized, multi-regional Phase 2 PROFECTA-II trial of afuresertib, described as the world’s first registration-directed clinical trial of an AKT kinase inhibitor to treat platinum-resistant ovarian cancer. Laekna is led by CEO Dr. Chris Lu and intends to use new funds to accelerate development of its core candidates.

Led · Equity · Mar 2020

Code Institute delivers online full-stack coding bootcamp courses to students globally and counts customers including BT, Facebook, Google and HubSpot. The company operates in four European countries as well as the USA, Canada and Singapore. Founded in 2015 and based in Dublin, Ireland, Code Institute has almost 2,000 students who have completed or are in the process of completing its Full Stack Coding Bootcamp course. Jim Cassidy is CEO. The company raised funding to support international expansion and to grow its global footprint. The core product is instructor-led online coding education aimed at enterprise customers and individual learners. Code Institute delivers certified, 3-month bootcamp-style full-stack software coding programs designed to give graduates job-ready skills. Its curriculum is fully accredited and certified by Edinburgh Napier University and was developed with an Industry Advisory Council including experts from PayPal, Morgan McKinley, Ogilvy, Accenture and Dell. Programs are offered online and in classroom formats. The company was founded in 2014 and is led by CEO Jim Cassidy. In 2016 it secured €500k in funding and plans to use the proceeds to develop a suite of future courses and to expand into international markets. Following the investment, Dr. Mícheál Ó Foghlú joined the company’s Advisory Council.

Led · Equity · Jun 2017

AltraTech is developing an affordable HIV viral load test intended for use in low- and middle-income countries. The company is based in Cork and is described as a developer of HIV diagnostic kits. Recently it raised almost €2.4m in a financing round led by a Bank of Ireland-linked fund and separately received a $441,437 grant from the Gates Foundation to accelerate product development. The new funding package is positioned to speed the test's development, though no revenue, user metrics, or commercialization timeline were disclosed in the articles. No additional operational or financial metrics were provided.

Led · Equity · Jan 2017

Corlytics provides an end-to-end regulatory intelligence and policy compliance platform, spanning regulatory horizon scanning, policy management and attestation. The company positions itself as the only solution with a fully integrated offering that helps clients align with evolving regulatory demands and proof-of-compliance requirements. Corlytics has invested heavily in innovation, with group R&D spending exceeding €50 million to date. Since 2020 the company has grown roughly 60% per annum and has roughly doubled its customer base. In 2023 Corlytics completed two acquisitions—ING SparQ and Clausematch—creating a platform that manages the entire regulatory risk value chain at scale. The firm plans to accelerate organic growth, pursue further M&A, and invest in its “intelligent content” offering that combines data, software and AI. Corlytics provides a proprietary data and real-time technology platform that uncovers and predicts avoidable compliance and operational risk for financially regulated firms, regulators and their professional advisers. The platform measures, predicts and calculates regulatory outcomes and impact, enabling customers and partners to understand their regulatory position and make more informed decisions. Led by CEO John Byrne, the company operates a global team of legal and regulatory experts, securities and risk practitioners, data scientists and seasoned technologists across Dublin, London, Boston and New York. Clients include the Financial Conduct Authority, the Bank of England, global regulators and tier one accountancy firms. The company raised €3m in venture capital and intends to use the funds to continue to scale internationally. In conjunction with the funding, senior figures from investors joined Corlytics’ board. Corlytics has developed a platform that enables global financial institutions to identify avoidable losses and fines using predictive risk analytics. Its technology helps banks minimize regulatory breaches by evaluating, benchmarking and managing market risk. The company plans to use the new funding to double its staff and grow operations. Corlytics was founded in 2013 and is led by CEO John Byrne. The company is Dublin-based and also has offices in London, New York and Boston. It raised €1m in the reported funding round.